trastuzumab-MCC-DM1

DRUG3 trials

Sponsors

Genentech, Inc.

Conditions

Metastatic Breast Cancer

Phase 1

Trastuzumab and Trastuzumab-MCC-DM1 Administered Intravenously and GDC-0941 Administered Orally to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed on Previous Trastuzumab-Based Therapy

CompletedNCT00928330

Genentech, Inc.Metastatic Breast Cancer

Start: 2009-07-31End: 2014-01-31Updated: 2016-11-02

A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen

CompletedNCT00932373

Genentech, Inc.Metastatic Breast Cancer

Start: 2006-04-30End: 2009-06-30Updated: 2015-08-26

Unknown Phase

A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer

Genentech, Inc.Metastatic Breast Cancer

Start: 2010-05-31Updated: 2017-02-15

Related Papers

Trastuzumab emtansine (T-DM1) in previously treated HER2-positive metastatic breast cancer (MBC): Results from an expanded access study.

Journal of Clinical Oncology2013-09-101 citations